Lilly is also running two other trials with eloralintide plus tirzepatide, including another mid-stage study in obese and overweight type 2 diabetes patients, with an initial completion date in June 2026, and a Phase I trial in nondiabetic individuals, scheduled to complete in October 2025
#medicaldevice #medicalsales #medicalsalesrep Catherine Renfroe Catherine Renfroe 3yCatherine Renfroe shared thisExcited to announce I will be attending Medical Sales College for the Spine and Orthopaedic Reconstruction & Trauma program in Plano, TX
Suspected adverse reactions should be reported through the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk or via the Yellow Card app), contributing to ongoing medication safety surveillance
As the key enzyme metabolizing APAP into NAPQI, cytochrome P450 enzymes are also considered to be intriguing target for the treatment of APAP-induced liver injury
Viral infections such as norovirus and rotavirus are more common causes, but bacterial infections can cause it too
doi: 10.1016/j.eclinm.2021.101019 265 DavenportTStevensSNessJVStevensJSnellC